Strategy of rational antidiabetic drugs application in type 2 diabetes mellitus

Abstract

Abstract: Type 2 diabetes mellitus is one of major chronic diseases in China, and its control is not optimistic. Antidiabetic drugs application is an important tool for the control of blood glucose . Diabetes medications by action mechanism and structure is divided into insulin secretagogues, biguanides, thiazolidinediones, glucosidase inhibitors, DPP-Ⅳ inhibitor, GLP-1, insulin and its analogs, etc.This paper overviews the clinical pharmacology mechanisms, characteristics and properties of commonly used antidiabetic drugs, and proposes the strategy of rational antidiabetic drugs application in type 2 diabetes mellitus, such as using insulin timely, simplicity principle, reasonable combination , individual principle and taking into account safety, cost .

Key words: Diabetes mellitus, Hypoglycemic agent, Insulin, Pharmacologic actions, Hypoglycemia

CLC Number:

R587.1

HE Yin-hui, XU Hai-yan, SUN Xia, XU Ai-hua, YE Wei-hong. Strategy of rational antidiabetic drugs application in type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 837-840.

References

[1] Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12): 1090-1101.
[2] Pan C, Yang W, Jia W, et al. Management of Chinese patients with type 2 diabetes, 1998-2006: the Diabcare-China surveys[J]. Curr Med Res Opin, 2009, 25(1): 39-45.
[3] Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin[J]. Diabetes Care, 2005, 28(9): 2093-2099.
[4] 中华医学会糖尿病分会. 2007年版中国2型糖尿病防治指南[J]. 中华内分泌代谢杂志, 2008, 24(2): 增录1-附录26.
[5] Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea[J]. Diabetes Res Clin Pract, 2009, 83(1): 106-116.
[6] Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes[J]. Diabetes Care, 2005, 28(4): 950-955.
[7] Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial[J]. Lancet, 2008, 371(9626): 1753-1760.
[8] Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time[J] ？ Am J Med, 2011, 124(1 Suppl): S19-S34.
[9] Fonseca V, Grunberger G, Gupta S, et al. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control[J]. Diabetes Care, 2003, 26(6): 1685-1690.
[10] Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus[J]. Endocr Pract, 2007, 13 (Suppl 1): 1-68.
[11] 中华医学会儿科学分会内分泌遗传代谢学组, 《中华儿科杂专》编辑委员会, The Subspecialty Group of Endocrinologic HaMD,等. 儿童及青少年糖尿病的胰岛素治疗指南(2010年版)[J]. 中华儿科杂志, 2010, 48(6): 431-435.
[12] Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J]. N Engl J Med, 2007, 356(24): 2457-2471.
[13] Olansky L. Do incretin-based therapies cause acute pancreatitis[J] ？ J Diabetes Sci Technol, 2010, 4(1): 228-229.
[14] International diabetes federation.2005 Global guideline for type 2 diabetes[EB/OL]. [2011-04-26] http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[4]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[5]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[6]	QUAN Haiyan, JIANG Xing, HE Lu. Recent progress of mitophagy in hepatic insulin resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 198-204.
[7]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[8]	WU Yi, FANG Fang, CHEN Ying, Fan Junwei. Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639.
[9]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[10]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[11]	HUANG Hao, XIAO Fang, JIA Hong, WANG Xiaoshuang, DUAN Yating. miR-138-5p protects β cell function by regulating HIF-1α in gestational diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 489-497.
[12]	WANG Chunjiang，SUN Wei，SUN Linli. Clinical characteristics of insulin autoimmune syndrome caused by methimazole in Chinese population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 209-213.
[13]	LIU Huanmiao, CHEN Zhuohui, WU Di, HUANG Xueting, WAN Qiquan. Insulin attenuates the inhibition effect of lipopolysaccharide on Na+-K+-ATPase α1 via PI3K/AKT and PI3K/ERK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 896-902.
[14]	QUAN Haiyan, LIU Yuhuan, YANG Li, YANG Fang, QIN Xuping. Improvement of CGRP on vascular endothelial cells insulin resistance via activation of cAMP/PPARγ/eNOS pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 615-622.
[15]	CHEN Yan, ZHU Lijun, FANG Zhengmei, ZHU Hui, JIN Yuelong, SHEN Chong, YAO Yingshui. Association of insulin-like growth factor(IGF)-1 polymorphisms and efficacy of antihypertensive drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 171-179.